NCT Number: NCT02720328
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
The purpose of this study is to investigate the preventability of serious adverse drug reactions (ADRs) related to the use of direct oral anticoagulants (DOACs). The investigators also aim at identifying the underlying causes of these preventable ADRs. The endpoint measurements will be compared with a group of patients taking vitamin-K antagonists (VKAs). For this purpose, a protocol for a prospective observational study was developed. The study was approved by the Ethics Committee of the CHU UCL Namur (site Godinne) and the Cliniques Universitaires Saint-Luc. Patients admitted to the emergency department of these two teaching hospitals with a thrombotic or a bleeding event while under DOAC or VKA are included. After a comprehensive medication history, the appropriateness of prescribing is evaluated, using an adapted version of the Medication Appropriateness Index. Causality, severity and preventability of adverse events are assessed by two pharmacists and two hematologists using predefined scales. Second, for cases of serious and preventable ADRs, semi-structured interviews are performed with general practitioners to understand the underlying causes of medication errors. Based on the results, risk-minimization strategies that specifically target the problems encountered in clinical practice will be proposed.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Cliniques Universitaires Saint-Luc, Brussels, Belgium
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Admitted to the emergency department
- Presenting a thrombotic or a bleeding event
- Prescribed NOAC (rivaroxaban, dabigatran etexilate or apixaban) or VKA
Treatment and study plan
Primary outcomes
-
Preventability of adverse drug reactions according to Hallas criteria
Time frame: Baseline
Secondary outcomes
-
Appropriateness of prescribing according to the Medication Appropriateness Index
Time frame: Baseline
Sponsors and collaborators
Lead sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Other
Registry information
Acronym: ADR-OAC
Important dates
- Study start
- 2015
- Primary completion
- 2016
- First posted
- Mar 25, 2016
- Registry last updated
- Mar 25, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT04263038
Anticoagulant-induced Bleeding, Bleeding
Woluwe-Saint-Lambert, Brussels Capital, Belgium
View Trial DetailsEvaluation of the LumiraDx Point of Care D-Dimer and CRP Tests
NCT04375982
Cardiovascular Diseases, Embolism and Thrombosis
Banning, California, United States
View Trial DetailsSafety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy
NCT04657120
Cancer, Cardiovascular Diseases
Antwerp, Belgium
View Trial DetailsRisk Stratification for Venous Thromboembolism in Hospitalized Medical Patients
NCT04439383
Cardiovascular Diseases, Deep Vein Thrombosis
Bern, Switzerland
View Trial Details